In a midstage trial, Viking’s experimental obesity treatment is showing promising results that could make it a strong rival in the weight loss drug market. The injectable version of Viking’s drug has shown even greater weight loss benefits compared to Eli Lilly’s Zepbound, causing Viking’s shares to rise by 120%. With a projected increase in Americans taking weight loss drugs by 2028, Viking’s drug has the potential to capture a significant share of this growing market.
Despite the positive data from Viking’s phase two trial, the company still faces challenges in manufacturing and commercializing its drug. Viking plans to conduct another phase two trial and may not launch the injection until later in the decade. The company’s late entrance into the market could hinder its ability to compete with established players like Eli Lilly and Novo Nordisk. However, Viking’s impressive data and intellectual property coverage make it an attractive target for acquisition or partnership with larger pharmaceutical companies.
Analysts are optimistic about the potential of Viking’s drug, especially with additional drugs in development and ongoing discussions with potential partners. Viking’s early-stage trial results on an oral version of its weight loss treatment, combined with its extended intellectual property coverage, make it a valuable asset in the weight loss drug market. As pharmaceutical companies continue to acquire smaller players in the obesity drug market, Viking’s innovative approach and promising results position it as a key player to watch in the coming years.